Endologix LLC (Endologix) is a medical equipment company that develops, manufactures and markets minimally invasive devices in treatment of aortic diseases. The company incorporates its patented technology for the treatment of Abdominal Aortic Aneurysms (AAA) and ALTO Abdominal Stent Graft System. The company’s AAA products are built on traditional minimally invasive endovascular repair (EVAR) platform or endovascular sealing (EVAS) platform and Ovation system. The company’s EVAR products include AFX endovascular AAA system, the VELA proximal endograft, the ovation abdominal stent graft system. Its ALTO products are developed with adaptive sealing technology, low profile delivery system, and shortest neck indication system specialized for anatomies, including tortuous iliacs and short necks. It has manufacturing facility in Irvine and Santa Rosa, California. The company sells products in the US and six other countries through direct sales force. It also sells products through third-party distributors and agents in Asia Pacific, Latin America, Europe, and other targeted international geographies. Endologix is headquartered in Irvine, California, the US.
This report is a source for data, analysis, and actionable intelligence on the company’s portfolio of pipeline products. The report provides key information about the company, its major products and brands.
The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage.
This report is a source for data, analysis, and actionable intelligence on the company’s portfolio of pipeline products. The report provides key information about the company, its major products and brands.
The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage.
Scope:
- The report reviews detailed company profile with information on business description, key company facts, major products and services, key competitors, key employees, locations and subsidiaries and recent developments
- The report analyzes all pipeline products in development for the company Endologix LLC
- The report provides pipeline analysis on all pipeline products of the company (by equipment type, by indication, by development stage, and by trial status)
- The report covers detailed information on each pipeline product with information on pipeline territory, stage of development, device class, regulatory path, indication(s), application(s) and estimated launch date
- The report provides detailed description of products in development, technical specification and functions
- The report also covers ongoing clinical trials (wherever applicable) with information on trial name, trial objective, sponsor, trial design , trial status and phase, estimated start and end date.
Reasons to Buy:
- Develop business strategies by understanding the trends and developments driving the medical devices pipeline and technology landscape
- Design and develop your product development, marketing and sales strategies by understanding the competitor portfolio
- To formulate effective Research & Development strategies
- Develop market-entry and market expansion strategies
- Exploit in-licensing and out-licensing opportunities by identifying products, most likely to ensure a robust return
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop competition strategies by identifying the status and likely launch of the competitors’ pipeline products through review of the clinical trials, stage and of development, etc
- Identify, understand and capitalize the next high-value products that your competitor would add in its portfolio
Table of Contents
- Endologix LLC Company Overview
- Endologix LLC Company Snapshot
- Endologix LLC Pipeline Products and Ongoing Clinical Trials Overview
- Endologix LLC - Pipeline Analysis Overview
- Business Description
- Endologix LLC - Key Facts
- Endologix LLC - Major Products and Services
- Endologix LLC Pipeline Products by Development Stage
- Endologix LLC Ongoing Clinical Trials by Trial Status
- Endologix LLC Pipeline Products Overview
- AFX2 Bifurcated Endograft System
- AFX2 Bifurcated Endograft System Product Overview
- AFX3
- AFX3 Product Overview
- AFX4
- AFX4 Product Overview
- Nellix 3.5
- Nellix 3.5 Product Overview
- Nellix CHEVAS
- Nellix CHEVAS Product Overview
- Nellix CHEVAS Clinical Trial
- Nellix EVAS System
- Nellix EVAS System Product Overview
- Nellix EVAS System Clinical Trial
- Nellix With Snorkels
- Nellix With Snorkels Product Overview
- Next Gen EVAS
- Next Gen EVAS Product Overview
- Ovation Thoracic Stent Graft System
- Ovation Thoracic Stent Graft System Product Overview
- Paravisceral System
- Paravisceral System Product Overview
- PQ Crossing Device
- PQ Crossing Device Product Overview
- PQ Snare
- PQ Snare Product Overview
- TORUS Stent Graft System
- TORUS Stent Graft System Product Overview
- TORUS Stent Graft System Clinical Trial
- Ventana 2
- Ventana 2 Product Overview
- Xpand BX Covered Stent
- Xpand BX Covered Stent Product Overview
- Endologix LLC - Key Competitors
- Endologix LLC - Key Employees
- Endologix LLC - Key Employee Biographies
- Endologix LLC - Locations And Subsidiaries
- Head Office
- Other Locations & Subsidiaries
- Recent Developments
- Endologix LLC, Recent Developments
- Jul 05, 2020: Endologix enters into an agreement with Deerfield Partners to take the company private
- May 11, 2020: Endologix, Inc. to Announce First Quarter 2020 Financial Results on May 11, 2020
- Feb 19, 2020: Endologix reports fourth quarter and fiscal year 2019 financial results
- Jan 10, 2020: PQ Bypass announces 100th patient in clinical study to evaluate percutaneous fem-pop bypass for extremely long blockages in leg arteries
- Dec 19, 2019: CMS approves coverage for PQ Bypass TORUS 2 IDE trial
- Nov 06, 2019: Endologix reports third quarter 2019 financial results
- Nov 04, 2019: PQ Bypass initiates pivotal study of next-generation advancement in Stent Graft Technology for Treatment of Patients with Peripheral Artery Disease
- Oct 29, 2019: Endologix comments on recent FDA update on Type III Endoleaks with AFX Endovascular AAA System
- Oct 28, 2019: Update on risk of type III endoleaks with use of Endologix AFX Endovascular AAA Graft Systems: FDA safety communication
- Oct 08, 2019: PQ Bypass announces unconditional IDE approval from U.S. FDA to start TORUS SFA Stent Graft Pivotal Study (TORUS-2)
- Appendix
- Methodology
- About the Publisher
- Contact the Publisher
- Disclaimer
- Endologix LLC Pipeline Products and Ongoing Clinical Trials Overview
- Endologix LLC Pipeline Products by Equipment Type
- Endologix LLC Pipeline Products by Indication
- Endologix LLC Ongoing Clinical Trials by Trial Status
- Endologix LLC, Key Facts
- Endologix LLC, Major Products and Services
- Endologix LLC Number of Pipeline Products by Development Stage
- Endologix LLC Pipeline Products Summary by Development Stage
- Endologix LLC Ongoing Clinical Trials by Trial Status
- Endologix LLC Ongoing Clinical Trials Summary
- AFX2 Bifurcated Endograft System - Product Status
- AFX2 Bifurcated Endograft System - Product Description
- AFX3 - Product Status
- AFX3 - Product Description
- AFX4 - Product Status
- AFX4 - Product Description
- Nellix 3.5 - Product Status
- Nellix 3.5 - Product Description
- Nellix CHEVAS - Product Status
- Nellix CHEVAS - Product Description
- Nellix CHEVAS - Prospective, Multicenter, Non-randomized Study with Consecutive, Eligible Subject Enrollment at Each Site, for the Evaluation of the ChEVAS System for Endovascular Repair of Paravisceral, Juxtarenal, and Pararenal Abdominal Aortic Aneurysms
- Nellix EVAS System - Product Status
- Nellix EVAS System - Product Description
- Nellix EVAS System - Multicenter, Observational, Registry to Assess Outcomes of Patients Treated With the CE Marked Nellix System for Endovascular Abdominal Aortic Aneurysm Repair
- Nellix EVAS System - Prospective, Multicenter, Single Arm Safety and Effectiveness Confirmatory Study of Endovascular Abdominal Aortic Aneurysm Repair Using the Nellix System IDE Study: EVAS 2 Confirmatory IDE Study
- Nellix With Snorkels - Product Status
- Nellix With Snorkels - Product Description
- Next Gen EVAS - Product Status
- Next Gen EVAS - Product Description
- Ovation Thoracic Stent Graft System - Product Status
- Ovation Thoracic Stent Graft System - Product Description
- Paravisceral System - Product Status
- Paravisceral System - Product Description
- PQ Crossing Device - Product Status
- PQ Crossing Device - Product Description
- PQ Snare - Product Status
- PQ Snare - Product Description
- TORUS Stent Graft System - Product Status
- TORUS Stent Graft System - Product Description
- TORUS Stent Graft System - Long Segment Lesion Peripheral Artery Revascularization Feasibility Study
- TORUS Stent Graft System - The PQ Bypass Pivotal IDE Intra-arterial Stent Graft Study for Occlusive and Re-stenotic Fem-pop Revascularization - 2 Trial: TORUS 2
- Ventana 2 - Product Status
- Ventana 2 - Product Description
- Xpand BX Covered Stent - Product Status
- Xpand BX Covered Stent - Product Description
- Endologix LLC, Key Employees
- Endologix LLC, Key Employee Biographies
- Endologix LLC, Subsidiaries
- Glossary
- Endologix LLC Pipeline Products by Equipment Type
- Endologix LLC Pipeline Products by Development Stage
- Endologix LLC Ongoing Clinical Trials by Trial Status
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- W. L. Gore & Associates Inc
- Medtronic Plc
- Cook Medical Inc
- St. Jude Medical LLC
- Baxter International Inc
- Lombard Medical Technologies Inc.
- Cardinal Health Inc
